Virtus Biotech ETF
BBP
25 hedge funds and large institutions have $41.7M invested in Virtus Biotech ETF in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
54% more capital invested
Capital invested by funds: $27M → $41.7M (+$14.6M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
4% less funds holding
Funds holding: 26 → 25 (-1)
6.65% less ownership
Funds ownership: 54.22% → 47.57% (-6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$9.08M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$3.91M |
| 3 |
Two Sigma Investments
New York
|
+$522K |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$362K |
| 5 |
LPL Financial
San Diego,
California
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.01M |
| 2 |
Jane Street
New York
|
-$904K |
| 3 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
-$429K |
| 4 |
Morgan Stanley
New York
|
-$404K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$371K |
BBP Hedge Fund Activity: Q2 2026 in Review
25 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2026, worth a combined $41.7M — up 54% from $27M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BBP positions and 7 closed out — a net gain of 1 holder — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Wealth Enhancement Advisory Services, opening a new position worth an estimated $9.08M. The largest seller was Susquehanna International Group, cutting an estimated $2.01M.
- 25 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2026, down from 26 in Q1 2026.
- Funds reported $41.7M of Virtus Biotech ETF stock for Q2 2026, up 54% quarter-over-quarter.
- 8 funds opened new Virtus Biotech ETF positions in Q2 2026 and 7 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q2 2026 was Wealth Enhancement Advisory Services, an estimated $9.08M added.
- The largest Virtus Biotech ETF seller in Q2 2026 was Susquehanna International Group, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2026.